Andrew Leask

18.1k total citations · 3 hit papers
230 papers, 14.7k citations indexed

About

Andrew Leask is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Andrew Leask has authored 230 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Molecular Biology, 85 papers in Pathology and Forensic Medicine and 47 papers in Dermatology. Recurrent topics in Andrew Leask's work include Connective Tissue Growth Factor Research (155 papers), Systemic Sclerosis and Related Diseases (82 papers) and Dermatologic Treatments and Research (46 papers). Andrew Leask is often cited by papers focused on Connective Tissue Growth Factor Research (155 papers), Systemic Sclerosis and Related Diseases (82 papers) and Dermatologic Treatments and Research (46 papers). Andrew Leask collaborates with scholars based in Canada, United Kingdom and United States. Andrew Leask's co-authors include David Abraham, Shiwen Xu, Carol M. Black, Alan Holmes, Christopher P. Denton, Shangxi Liu, Roel Goldschmeding, Ingrid E. Blom, Susan Sa and Mark Eastwood and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Andrew Leask

225 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TGF‐β signaling and the fibrotic response

2004 1.9k citations Andrew Leask, David Abraham profile →
Potential Therapeutic Targets for Cardiac Fibrosis

2010 569 citations Andrew Leask profile →
All in the CCN family: essential matricellular signaling modulators emerge from the bunker

2006 560 citations Andrew Leask, David Abraham Journal of Cell Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Leask Canada	63	8.7k	3.0k	2.1k	1.6k	1.5k	230	14.7k
Hironobu Ihn Japan	58	4.5k 0.5×	4.1k 1.4×	1.8k 0.9×	448 0.3×	2.1k 1.4×	384	11.8k
Maria Trojanowska United States	61	4.6k 0.5×	4.0k 1.3×	1.7k 0.8×	351 0.2×	1.7k 1.1×	171	10.0k
John Varga United States	75	6.4k 0.7×	7.6k 2.5×	6.7k 3.2×	2.5k 1.5×	3.0k 1.9×	279	20.2k
Robert Lafyatis United States	66	5.3k 0.6×	4.6k 1.5×	2.9k 1.4×	346 0.2×	1.7k 1.1×	236	14.2k
Renate E. Gay Switzerland	65	5.5k 0.6×	1.9k 0.6×	1.2k 0.6×	743 0.5×	656 0.4×	174	13.4k
Gary R. Grotendorst United States	50	7.0k 0.8×	1.5k 0.5×	1.4k 0.7×	355 0.2×	737 0.5×	100	12.1k
Alain Mauviel France	64	6.3k 0.7×	1.0k 0.3×	925 0.4×	455 0.3×	960 0.6×	145	11.2k
Alexis Desmoulière France	55	3.8k 0.4×	705 0.2×	1.7k 0.8×	723 0.4×	1.5k 1.0×	158	14.0k
Lawrence F. Brown United States	75	13.7k 1.6×	942 0.3×	2.4k 1.1×	779 0.5×	1.1k 0.7×	111	23.2k
Kazuhiko Takehara Japan	69	4.3k 0.5×	6.8k 2.2×	2.5k 1.2×	357 0.2×	3.7k 2.4×	375	15.9k

Countries citing papers authored by Andrew Leask

Since Specialization

Citations

This map shows the geographic impact of Andrew Leask's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Leask with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Leask more than expected).

Fields of papers citing papers by Andrew Leask

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Leask. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Leask. The network helps show where Andrew Leask may publish in the future.

Co-authorship network of co-authors of Andrew Leask

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Leask. A scholar is included among the top collaborators of Andrew Leask based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Leask. Andrew Leask is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tejera‐Muñoz, Antonio, Marcelino Cortés, Lucía Tejedor-Santamaria, et al.. (2024). Ccn2 Deletion Reduces Cardiac Dysfunction, Oxidative Markers, and Fibrosis Induced by Doxorubicin Administration in Mice. International Journal of Molecular Sciences. 25(17). 9617–9617. 1 indexed citations

Leask, Andrew, et al.. (2024). A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis. Expert Opinion on Investigational Drugs. 33(3). 279–285. 2 indexed citations

Xu, Shiwen, John Nguyen, David E. Carter, et al.. (2023). Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Annals of the Rheumatic Diseases. 82(9). 1191–1204. 15 indexed citations

Leask, Andrew, et al.. (2023). Back to the future: targeting the extracellular matrix to treat systemic sclerosis. Nature Reviews Rheumatology. 19(11). 713–723. 28 indexed citations

Zhao, Kaiqiong, Tianyuan Lu, Kathleen Klein, et al.. (2023). Novel insights into systemic sclerosis using a sensitive computational method to analyze whole-genome bisulfite sequencing data. Clinical Epigenetics. 15(1). 96–96. 1 indexed citations

Xu, Shiwen, et al.. (2021). Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. Journal of Cell Communication and Signaling. 15(1). 71–80. 29 indexed citations

Gerarduzzi, Casimiro, Ursula Hartmann, Andrew Leask, & Elliot Drobetsky. (2020). The Matrix Revolution: Matricellular Proteins and Restructuring of the Cancer Microenvironment. Cancer Research. 80(13). 2705–2717. 71 indexed citations

Kanakis, Ioannis, Peter Milner, Andrew Leask, et al.. (2020). Post-traumatic osteoarthritis development is not modified by postnatal chondrocyte deletion of Ccn2. Disease Models & Mechanisms. 13(7). 5 indexed citations

Dwivedi, Nidhi, Shixin Tao, Abeda Jamadar, et al.. (2020). Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease. Journal of the American Society of Nephrology. 31(8). 1697–1710. 23 indexed citations

10.

Lee, Sangmi, et al.. (2020). A CTGF-YAP Regulatory Pathway Is Essential for Angiogenesis and Barriergenesis in the Retina. iScience. 23(6). 101184–101184. 41 indexed citations

11.

Xu, Shiwen, Yizhi Xiao, Shangxi Liu, et al.. (2019). CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. SHILAP Revista de lepidopterología. 3. 100009–100009. 17 indexed citations

12.

Elliott, Christopher G., Jiarong Wang, John T. Walker, et al.. (2018). Periostin and CCN2 Scaffolds Promote the Wound Healing Response in the Skin of Diabetic Mice. Tissue Engineering Part A. 25(17-18). 1326–1339. 16 indexed citations

13.

Ercan, Ebru, Juliette M. Han, Alessia Di Nardo, et al.. (2017). Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex. The Journal of Experimental Medicine. 214(3). 681–697. 78 indexed citations

14.

Leask, Andrew. (2013). Integrin β 1: A Mechanosignaling Sensor Essential for Connective Tissue Deposition by Fibroblasts. Advances in Wound Care. 2(4). 160–166. 48 indexed citations

15.

Leask, Andrew. (2013). The Contribution of Peroxisome Proliferator–Activated Receptor Gamma to Cutaneous Wound Healing. Advances in Wound Care. 2(2). 69–73. 11 indexed citations

16.

Leask, Andrew. (2013). Focal Adhesion Kinase: A Key Mediator of Transforming Growth Factor Beta Signaling in Fibroblasts. Advances in Wound Care. 2(5). 247–249. 46 indexed citations

17.

Nikitorowicz-Buniak, Joanna, Shiwen Xu, Andrew Leask, et al.. (2011). Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. PubMed. 4(1). 13–13. 18 indexed citations

18.

Leask, Andrew, Shiwen Xu, Korsa Khan, et al.. (2008). Loss of protein kinase Cϵ results in impaired cutaneous wound closure and myofibroblast function. Journal of Cell Science. 121(20). 3459–3467. 26 indexed citations

19.

Chen, Yunliang, Shiwen Xu, Laura Kennedy, et al.. (2005). Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-β/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK. American Journal Of Pathology. 167(6). 1699–1711. 119 indexed citations

20.

Leask, Andrew, Daniel J. Pennington, Shiwen Xu, et al.. (2002). Dysregulation of transforming growth factor beta signaling in scleroderma - Overexpression of endoglin in cutaneous scleroderma fibroblasts (vol 46, pg 1857, 2002). UCL Discovery (University College London). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact